Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mineralys Therapeutics, Inc.

16.47
-0.2800-1.67%
Volume:365.05K
Turnover:6.16M
Market Cap:1.03B
PE:-4.50
High:17.29
Open:16.43
Low:16.33
Close:16.75
Loading ...

Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
10 Mar

Mineralys Therapeutics Shares Hit 52-Week High on Hypertension Study Results

Dow Jones
·
10 Mar

Mineralys Therapeutics Shares up 31% After Co's Blood Pressure Drug Meets Goal in Trials

THOMSON REUTERS
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin

Reuters
·
10 Mar

Mineralys Therapeutics Says Lorundrostat Met Trial Endpoints for Treating Hypertension; Shares Up Pre-Bell

MT Newswires Live
·
10 Mar

Mineralys Therapeutics Shares Resume Trading, Jump 40% Premarket After Co's Blood Pressure Drug Meets Goal in Trials

THOMSON REUTERS
·
10 Mar

CORRECTED-UPDATE 2-Mineralys' blood pressure drug meets goal in trials, shares soar

Reuters
·
10 Mar

Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension

Dow Jones
·
10 Mar

Mineralys Therapeutics' blood pressure drug meets goal in trials

Reuters
·
10 Mar

BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension

Reuters
·
10 Mar

Mineralys Therapeutics Announces Positive Topline Results From Launch-Htn and Advance-Htn Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

THOMSON REUTERS
·
10 Mar

Mineralys Therapeutics Inc: Launch-Htn Met Its Primary Endpoint

THOMSON REUTERS
·
10 Mar

Mineralys Therapeutics Inc: Lorundrostat Demonstrated a Favorable Safety and Tolerability Profile in Both Pivotal Trials

THOMSON REUTERS
·
10 Mar

Mineralys Therapeutics Shares Halted for News Pending Premarket

THOMSON REUTERS
·
10 Mar

Stocks to Watch: Cognizant Technology Solutions, Mineralys Therapeutics, PDF Solutions

Dow Jones
·
08 Mar

Mineralys Therapeutics Rises Ahead of Hypertension-Drug Trial Data

Dow Jones
·
08 Mar